Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06976853 · ClinicalTrials.gov registry record · Phase 2
Moving Beyond Inflammation as a Therapeutic Target for Crohn's Disease
A Phase 2 study of Crohn Disease (CD), sponsored by Washington University School of Medicine.
- Recruiting
- Registry status
- Phase 2
- Development phase
- 60
- Enrollment target
- 3
- Study locations
NCT06976853 is a Phase 2 study of Crohn Disease (CD) that is actively recruiting participants, run by Washington University School of Medicine. The registered enrollment target is 60 participants, below the 81-participant average among 5 other Crohn Disease (CD) trials with a reported enrollment target (26% lower). The trial reports 3 study locations across 3 states.
The verdict
NCT06976853, a Phase 2 study of Crohn Disease (CD), is actively recruiting participants, sponsored by Washington University School of Medicine.
- RECRUITING
- Registry status
- Phase 2
- Development phase
- 60 participants
- Enrollment target
- 3
- Study locations
Study Summary
The purpose of this research study is to evaluate what type of treatment will be beneficial for people with Crohn's disease and difficult to treat inflammation in the small bowel. Current therapies are used to control the inflammation due to Crohn's disease in your digestive tract. In some patients, those therapies are not sufficient to fully treat the disease. This objective of this study is to evaluate the efficacy of a different type of therapy, tirzepatide, that may promote healing of the affected intestinal segment. To evaluate the efficacy of this medication, a member of the research team will ask patients questions about how they feel and observe whether this medication heals the their bowel at colonoscopy. A member of the research team will also use blood samples, stool samples and samples of the small intestine taken during a colonoscopy to understand how tirzepatide helps heal the intestine.
Conditions Studied
Interventions
- DRUG Tirzepatide
- DRUG Standard of care treatment
Study Locations (3)
California
- Cedars-Sinai Medical Center - Beverly Hills
Missouri
- Washington University School of Medicine - St Louis
New York
- Icahn School of Medicine at Mount Sinai - New York
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 60 participants |
| Start Date | 2025-05-13 |
| Est. Completion | 2028-08 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06976853
The ClinicalTrials.gov registry entry for NCT06976853 describes a study currently listed as recruiting, categorized as Phase 2. The registered enrollment target is 60 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 81-participant average among 5 other Crohn Disease (CD) trials with a reported enrollment target (26% lower). The listed sponsor is Washington University School of Medicine, which has 1,502 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Crohn Disease (CD) appearing as the primary indexed condition, and to 2 interventions - of which Tirzepatide is the first listed.
NCT06976853 reports 3 study locations spanning 3 distinct geographic areas - top geographies include California, Missouri, New York.
Frequently Asked Questions
What is clinical trial NCT06976853 about?
NCT06976853 is a clinical study titled "Moving Beyond Inflammation as a Therapeutic Target for Crohn's Disease". The purpose of this research study is to evaluate what type of treatment will be beneficial for people with Crohn's disease and difficult to treat inflammation in the small bowel. Current therapies are used to control the inflammation due to Crohn's disease in your digestive tract. In some patients,...
What is the current status of trial NCT06976853?
This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 60 participants. The study started on 2025-05-13. Estimated completion is 2028-08.
What conditions does trial NCT06976853 study?
This clinical trial studies the following conditions: Crohn Disease (CD).
What interventions are being tested in trial NCT06976853?
The interventions under investigation include: Tirzepatide (DRUG), Standard of care treatment (DRUG).
Who is sponsoring clinical trial NCT06976853?
This trial is sponsored by Washington University School of Medicine, which has 1,502 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06976853 being conducted?
This trial has 3 study locations across California, Missouri, New York. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Crohn Disease (CD)
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
HB-adMSCs for the Treatment of Crohn's Disease
RECRUITING · Phase 2
-
Cranberry and Gut Health in Crohn's Disease
RECRUITING · Early Phase 1
-
Evaluation of the SMART IBD App in Pediatric IBD
RECRUITING · NA
-
Assessment and Educational Intervention to Reduce Ultra-processed Food Consumption in Pediatric Patients With IBD
RECRUITING
-
ALPCO/Calprotectin CLIA Assay: Expected Values of Calprotectin in Healthy Subjects
RECRUITING
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.